TY - JOUR
T1 - Patient perceptions of treatment-free remission in chronic myeloid leukemia.
AU - Villemagne Sanchez, Lucia
AU - O'Callaghan, Clare
AU - Gough, Karla
AU - Hall, Karen
AU - Kashima, Yoshihisa
AU - Seymour, John
AU - Schofield, Penelope
AU - Ross, David
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Around half of patients with chronic myeloid leukemia (CML) who achieve a stable deep molecular response would remain in treatment-free remission (TFR) if their tyrosine kinase inhibitors (TKIs) were stopped. TFR is increasingly becoming a goal of treatment. Eighty-seven patients answered a survey exploring patient perceptions of TFR, incorporating CML-specific factors (disease history, treatment toxicity, and adherence) and questions concerning health beliefs. 81% of participants (95% CI: 72%–89%) indicated that they would be willing to attempt TFR. No demographic or CML-related variable in the survey was significantly associated with willingness. In qualitative analysis, the commonest motivations for TFR included TKI toxicity (n = 26) and convenience (n = 18). The leading reason for reluctance was fear of consequences of stopping TKI (n = 16). Reluctance was often associated with needs for additional information or incomplete understanding of the current data. Understanding patient motivations and concerns is important if TFR is to become a part of CML management.
AB - Around half of patients with chronic myeloid leukemia (CML) who achieve a stable deep molecular response would remain in treatment-free remission (TFR) if their tyrosine kinase inhibitors (TKIs) were stopped. TFR is increasingly becoming a goal of treatment. Eighty-seven patients answered a survey exploring patient perceptions of TFR, incorporating CML-specific factors (disease history, treatment toxicity, and adherence) and questions concerning health beliefs. 81% of participants (95% CI: 72%–89%) indicated that they would be willing to attempt TFR. No demographic or CML-related variable in the survey was significantly associated with willingness. In qualitative analysis, the commonest motivations for TFR included TKI toxicity (n = 26) and convenience (n = 18). The leading reason for reluctance was fear of consequences of stopping TKI (n = 16). Reluctance was often associated with needs for additional information or incomplete understanding of the current data. Understanding patient motivations and concerns is important if TFR is to become a part of CML management.
KW - Chronic myeloid leukemia
KW - quality of life
KW - treatment-free remission
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85020488026&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1337114
DO - 10.1080/10428194.2017.1337114
M3 - Article
SN - 1042-8194
VL - 59
SP - 406
EP - 415
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -